Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes

Diab Vasc Dis Res. 2008 Jun;5(2):135-7. doi: 10.3132/dvdr.2008.022.


The purpose of this study was to assess the effect of rosiglitazone on bioavailable, free and total testosterone levels in hypogonadal men with type 2 diabetes. Sixteen type 2 diabetic men with hypogonadism were studied before and after administration of rosiglitazone (8 mg/day) for six months, with assessments performed every two months on two consecutive days. We measured testosterone and sex hormone binding globulin (SHBG), visceral adiposity, high-sensitivity CRP (hs-CRP), lipids, microalbuminuria and blood pressure. There was a significant increase in free (p=0.01), bioavailable (p=0.007) and total testosterone (p=0.002), as well as SHBG (p=0.03) levels, with rosiglitazone treatment. Waist circumference and waist / hip ratio decreased with the improvement in insulin sensitivity and glycaemic control (p=0.01). There was also a significant reduction in hs-CRP (p=0.02) and urinary albumin excretion. No significant effect on blood pressure or the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol (LDL to HDL) was seen. In conclusion, the insulin-sensitiser rosiglitazone increases bioavailable, free and total testosterone and SHBG levels in hypogonadal men with type 2 diabetes.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiposity / drug effects
  • Adult
  • Aged
  • Albuminuria / etiology
  • Albuminuria / prevention & control
  • Blood Pressure
  • Body Size / drug effects*
  • C-Reactive Protein / metabolism
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Hypogonadism / complications
  • Hypogonadism / drug therapy*
  • Hypogonadism / metabolism
  • Hypogonadism / physiopathology
  • Intra-Abdominal Fat / drug effects
  • Lipids / blood
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Pilot Projects
  • Rosiglitazone
  • Sex Hormone-Binding Globulin / metabolism
  • Testosterone / blood*
  • Thiazolidinediones / therapeutic use*
  • Treatment Outcome
  • Up-Regulation


  • Hypoglycemic Agents
  • Lipids
  • Sex Hormone-Binding Globulin
  • Thiazolidinediones
  • Rosiglitazone
  • Testosterone
  • C-Reactive Protein